A search to predict potential for drug-induced cardiovascular toxicity

Toxicologic Pathology

Volumn 34, Issue 1, 2006, Pages 75-80

  Hamlin, Robert ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Cardiovascular toxicity; QT; Safety pharmacology; Torsade de pointes; Ventricular repolarization

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CISAPRIDE; DOFETILIDE; DOXORUBICIN; ERYTHROMYCIN; FENFLURAMINE; FEXOFENADINE; METHOXAMINE; NEUROLEPTIC AGENT; POTASSIUM CHANNEL HERG; PROKINETIC AGENT; QUINIDINE; ROFECOXIB; TERFENADINE; TROPONIN; VERATRIDINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALKALINE PHOSPHATASE BLOOD LEVEL; ATRIOVENTRICULAR CONDUCTION; CARDIOTOXICITY; CARDIOVASCULAR FUNCTION; CONFIDENCE INTERVAL; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG SAFETY; ECG ABNORMALITY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; GENETIC POLYMORPHISM; HEART DEPOLARIZATION; HEART FAILURE; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; MITOCHONDRION SWELLING; MORBIDITY; MORTALITY; NONHUMAN; PHARMACOGENOMICS; POPULATION; PRIORITY JOURNAL; QRS COMPLEX; QT PROLONGATION; REVIEW; SINUS NODE; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TORSADE DES POINTES; URTICARIA;

ANIMALS; ANIMALS, LABORATORY; CARDIOVASCULAR SYSTEM; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; RABBITS; TACHYCARDIA; TOXICITY TESTS;

EID: 33644662061     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1080/01926230500419439     Document Type: Review

References (39)

1. Abernethy, D. R., and Flockhart, D. A. (2000). Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. Circulation 101, 1749-53.
2. Ben-David, J., and Zipes, D. P. (1990). Alpha-adrenoceptor stimulation and blockade modulates cesium-induced early after-depolarizations and ventricular tachyarrhythmias in dogs. Circulation 82, 225-33.
3. Carlsson, L., Abrahamsson, C., Andersson, B., Duker, G., and Schiller-Linhardt, G. (1993). Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early after-depolarisations. Cardiovasc Res 27, 2186-93.
4. Chachin, M., and Kurachi, Y. (2002). Evaluation of pro-arrhythmic risk of drugs due to QT interval prolongation by the HERG expression system. Nippon Yakurigaku Zasshi 119, 345-51.
5. Cheng, J., Niwa, R., Kamiya, K., Toyama, J., and Kodama, I. (1999). Carvedilol blocks the repolarizing K+ currents and the L-type Ca++ current in rabbit ventricular myocytes. Eur J Pharmacol 376, 189-201.
6. Committee for Proprietary Medicinal Products. (1997). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. (CPMP/986/96) European Medicines Agency (EMEA), London.
7. Cranefield, P., and Wit, A. L. (1979). Cardiac arrhythmias. Annu Rev Physiol 41, 459-72.
8. Dessertenne, F. (1966). La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur Vaiss 59, 263-72.
9. European Agency for the Evaluation of Medicinal Products (EMEA): Committee for Proprietary Medicinal Products (CMPMP) (1997). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. December 17, 1997, London, UK.
10. Ficker, E., Kuryshev, Y. A., Dennis, A. T., Obejero-Paz, C., Wang, L., Hawryluk, P., Wible, B. A., and Brown, A. M. (2004). Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66, 33-44.
11. Food and Drug Administration, Center for Drug Evaluation and Research (2000). Psychopharmacologic Drugs Advisory Committee Proceedings, Wednesday, July 19, 2000 (transcript).
12. Fossa, A. A., Wisialowski, T., Wolfgang, E., Wang, E., Avery, M., Raunig, D. L., and Fermini, B. (2004). Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. Eur J Pharmacol 486, 209-21.
13. Frey, W. (1918). Weitere erfahrungen mit chinidin bei absoluter herzunregelmäßigkeit. Wien Med Wschr 55, 849-53.
14. Fung, M. C., Hsiao-hui Wu, H., Kwong, K., Hornbuckle, K., and Muniz, E. (2000). Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades - 1969-1998. Pharmacoepidemiol Drug Saf 9, S24-S25.
15. Gbadebo, T. D., Trimble, R. W., Khoo, M. S., Temple, J., Roden, D. M., and Anderson, M. E. (2002). Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation 105, 770-4.
16. Honig, P. K., Wortham, D. C., Zamani, K., Conner, D. P., Mullin, J. C., and Cantilena, L. R. (1993). Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. J Am Med Assoc 269, 1513-18.
17. [Erratum, JAMA (1993). 269, 2088.]
18. 2+ current. Circlation Res 64, 977-90.
19. Jervell, A., and Lange-Nielsen, F. (1957). Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval, and sudden death. Am Heart J 54, 59-68.
20. Kannel, W. (2000). Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 85, 251-5.
21. Kuryshev, Y. A., Ficker, E., Wang, L., Hawryluk, P., Dennis, A. T., Wible, B. A., Brown, A. M., Kang, J., Chen, X. L., Sawamura, K., Reynolds, W., and Rampe, D. (2005). Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312, 316-23.
22. Liu, X. K., Katchman, A., Ebert, S. N., and Woosley, R. L. (1998). The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. J Pharmacol Exp Ther 287, 877-83.
23. Marks, A. (2000). Cardiac in tracellular release channels - role in heart failure. Circulation Res 87, 8-11.
24. Moss, A. J. (2002). T-wave patterns associated with the hereditary long QT syndrome. Card Electrophysiol Rev 6, 311-5.
25. Napolitano, C., Schwartz, P. J., Brown, A. M., Ronchetti, E., Bianchi, L., Pinnavaia, A., Acquaro, G., and Priori, S. G. (2000). Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 11, 691-96.
26. Nuss, H., Kaab, S., Kass, D., Tomaselli, G. F., and Marban, E. (1999). Cellular basis of ventricular arrhythmias and abnormal automaticity in heart failure. Am J Physiol 277, H80-H91.
27. Priori, S. G., Pandit, S. V., Rivolta, I., Berenfeld, O., Ronchetti, E., Dhamoon, A., Napolitano, C., Anumonwo, J., Raffaele, di Barletta, M., and Gudapakkam, S., Bosi, G., Stramba-Badiale, M., and Jalife, J. (2005). A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 96, 800-7.
28. Priori, S. G., Schwartz, P. J., Napolitano, C., Bloise, R., Ronchetti, E., Grillo, M., Vicentini, A., Spazzolini, C., Nastoli, J., Bottelli, G., Folli, R., and Cappelletti, D. (2003). Risk stratification in the long-QT syndrome. N Engl J Med 348, 1866-74.
29. Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K., Strang, I., Sullivan, A. T., Wallis, R., Camm, A. J., and Hammond, T. G. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58, 32-45.
30. Roden, D. M. (2004). Drug-induced prolongation of the QT interval. N Engl J Med 350, 1013-22.
31. Salle, P., Rey, J. L., Bernasconi, P., Quiret, J. C., and Lombaert, M. (1985). Torsades de pointe. Apropos of 60 cases (in French). Ann Cardiol Angiol (Paris) 34, 381-88.
32. Sanguinetti, M. C., Jiang, C., Curran, M. E., and Keating, M. T. (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81, 299-307.
33. Shah, R. R. (2004). Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 27, 145-72.
34. Temple, R. J., and Himmel, M. H. (2002). Safety of newly approved drugs: implications for prescribing. J Am Med Assoc 287, 2273-75.
35. Torp-Pedersen, C., Moller, M., Bloch-Thomsen, P. E., Kober, L., Sandoe, E., Egstrup, K., Agner, E., Carlsen, J., Videbaek, J., Marchant, B., and Camm, A. J. (1999). Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341, 857-65.
36. Vos, M., Verduyn, S., Gorgels, A., Lipcsei, G. C., and Wellens, H. J. (1995). Reproducible induction of EADs and TdP arrhythmias by D-sotolol and pacing in dogs with chronic AV block. Circulation 91, 864-72.
37. Watanabe, O., Okumura, T., Takeda, H., Nakamura, W., Segawa, K., Ito, H., and Yoshimoto, N. (1999). Nicorandil, a potassium channel opener, abolished torsades de pointes in a patient with complete atrioventricular block. Pacing Clin Electrophysiol 22, 686-88.
38. Woosley, R. L. (2000). Drug labeling revisions - Guaranteed to fail? J Am Med Assoc 284, 3047-9.
39. Yang, T., and Roden, D. M. (1996). Extracellular potassium modulation of drug block of IKr: implications for torsades de pointes and reverse use-dependence. Circulation 93, 407-11.